Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial

Digital

Autores:: Bajaj, Harpreet S.
Gerstein, Hertzel C.
Rao-Melacini, Purnima
Basile, Jan
Colhoun, Helen
Conget, Ignacio
Cushman, William C.
Dagenais, Gilles R.
Franek, Edward
Hanefeld, Markolf
Keltai, Matyas
Lakshmanan, Mark
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pirags, Valdis
Pogosova, Nana
Probstfield, Jeffrey
Raubenheimer, Peter
Ryden, Lars
Shaw, Jonathan E.
Sheu, Wayne H-H.
Xavier, Denis

Tipo de recurso:: Article of journal

Fecha de publicación:: 2021

Institución:: Universidad de Santander

Repositorio:: Repositorio Universidad de Santander

Idioma:: eng

id	RUDES2_89ea707c6a8492ead3cb49b71134969e
oai_identifier_str	oai:repositorio.udes.edu.co:001/6141
network_acronym_str	RUDES2
network_name_str	Repositorio Universidad de Santander
repository_id_str
dc.title.spa.fl_str_mv	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
spellingShingle	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title_short	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title_full	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title_fullStr	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title_full_unstemmed	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
title_sort	Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial
dc.creator.fl_str_mv	Bajaj, Harpreet S. Gerstein, Hertzel C. Rao-Melacini, Purnima Basile, Jan Colhoun, Helen Conget, Ignacio Cushman, William C. Dagenais, Gilles R. Franek, Edward Hanefeld, Markolf Keltai, Matyas Lakshmanan, Mark Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pirags, Valdis Pogosova, Nana Probstfield, Jeffrey Raubenheimer, Peter Ryden, Lars Shaw, Jonathan E. Sheu, Wayne H-H. Xavier, Denis
dc.contributor.author.none.fl_str_mv	Bajaj, Harpreet S. Gerstein, Hertzel C. Rao-Melacini, Purnima Basile, Jan Colhoun, Helen Conget, Ignacio Cushman, William C. Dagenais, Gilles R. Franek, Edward Hanefeld, Markolf Keltai, Matyas Lakshmanan, Mark Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pirags, Valdis Pogosova, Nana Probstfield, Jeffrey Raubenheimer, Peter Ryden, Lars Shaw, Jonathan E. Sheu, Wayne H-H. Xavier, Denis
dc.contributor.researchgroup.spa.fl_str_mv	Masira
description	Digital
publishDate	2021
dc.date.issued.none.fl_str_mv	2021-08-01
dc.date.accessioned.none.fl_str_mv	2022-02-23T23:03:55Z
dc.date.available.none.fl_str_mv	2022-02-23T23:03:55Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.1016/S2213-8587(21)00115-7
dc.identifier.uri.none.fl_str_mv	https://repositorio.udes.edu.co/handle/001/6141
url	https://doi.org/10.1016/S2213-8587(21)00115-7 https://repositorio.udes.edu.co/handle/001/6141
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.citationendpage.spa.fl_str_mv	490
dc.relation.citationissue.spa.fl_str_mv	8
dc.relation.citationstartpage.spa.fl_str_mv	484
dc.relation.citationvolume.spa.fl_str_mv	9
dc.relation.indexed.spa.fl_str_mv	Scopus
dc.relation.ispartofjournal.spa.fl_str_mv	The Lancet Diabetes and Endocrinology
dc.rights.spa.fl_str_mv	© 2021 The Authors, Elsevier Ltd. All rights reserved.
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_14cb
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/closedAccess
dc.rights.creativecommons.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv	© 2021 The Authors, Elsevier Ltd. All rights reserved. Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv	closedAccess
dc.format.extent.spa.fl_str_mv	7 p
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	The Lancet
dc.publisher.place.spa.fl_str_mv	Reini Unido
dc.source.spa.fl_str_mv	https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltext
institution	Universidad de Santander
bitstream.url.fl_str_mv	https://repositorio.udes.edu.co/bitstreams/7cf70863-3f52-4a94-a1f3-445f29a5f6f7/download https://repositorio.udes.edu.co/bitstreams/79a016d4-2af4-49f8-9061-b2984dd75356/download https://repositorio.udes.edu.co/bitstreams/283db921-8590-4525-af6c-21251832c979/download https://repositorio.udes.edu.co/bitstreams/c94069b0-7a29-4f6f-8f72-7f157d9bc885/download
bitstream.checksum.fl_str_mv	68d151b14479f430e7af476f1081f029 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 bda582e577ed99e2df04b2fed3182157
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Universidad de Santander
repository.mail.fl_str_mv	soporte@metabiblioteca.com
_version_	1814158673786699776
spelling	Bajaj, Harpreet S.78d26b08-560f-4458-9c6c-f91d482448ba-1Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Rao-Melacini, Purnima4a704681-2187-4ddd-b2c1-f8e681c77274-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Colhoun, Helen1824ca33-240e-46a3-aa60-6b80d5c57567-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Dagenais, Gilles R.f72492d7-dc96-43b0-9237-b00656585504-1Franek, Edwardc8fa48cd-c0c0-4e99-ad2b-29843fba16c4-1Hanefeld, Markolf411c9d9d-d3a2-4a87-b8e7-dbd8bc7c968e-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pirags, Valdisc43a25fe-51ee-4b71-863e-54b03868e125-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Raubenheimer, Peterbcbacea4-c23a-4587-9d31-1afcd9e0194e-1Ryden, Larse8666dad-aab3-446a-9e58-5e23a391873f-1Shaw, Jonathan E.bee14056-7326-4051-b756-4d809e9c79f8-1Sheu, Wayne H-H.a2436758-4d4a-4c6f-9759-0c03ccab64e4-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Masira2022-02-23T23:03:55Z2022-02-23T23:03:55Z2021-08-01DigitalBackground Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether dulaglutide's effect on erectile dysfunction was consistent with its effect on other diabetes-related outcomes. Methods The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial was a double-blind, placebo-controlled randomised trial of the effect of dulaglutide on cardiovascular outcomes. REWIND was done at 371 sites in 24 countries. Men and women aged older than 50 years with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, were randomly assigned (1:1) to receive either dulaglutide or placebo. Participating men were offered the opportunity to complete the standardised International Index of Erectile Function (IIEF) questionnaire at baseline, 2 years, 5 years, and study end. We did an exploratory analysis, in which we included participants who completed a baseline and at least 1 follow-up IIEF questionnaire. The primary outcome for these analyses was the first occurrence of moderate or severe erectile dysfunction following randomisation, assessed by the erectile function subscores on IIEF. This analysis was part of the REWIND trial, which is registered with ClinicalTrials.gov, NCT01394952. Findings Between Aug 18, 2011, and Aug 14, 2013, 3725 (70·1%) of 5312 male participants with a mean age of 65·5 years (SD 6·4 years) were analysed, of whom 1487 (39·9%) had a history of cardiovascular disease, and 2104 (56·5%) had moderate or severe erectile dysfunction at baseline. The incidence of erectile dysfunction following randomisation was 21·3 per 100 person-years in the dulaglutide group and 22·0 per 100 person-years in the placebo group (HR 0·92, 95% CI 0·85–0·99, p=0·021). Men in the dulaglutide group also had a lesser fall in erectile function subscore compared with the placebo group, with a least square mean difference of 0·61 (95% CI 0·18–1·05, p=0·006). Interpretation Long-term use of dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes.Ciencias Médicas y de la Salud7 papplication/pdfhttps://doi.org/10.1016/S2213-8587(21)00115-7https://repositorio.udes.edu.co/handle/001/6141engThe LancetReini Unido49084849ScopusThe Lancet Diabetes and Endocrinology© 2021 The Authors, Elsevier Ltd. All rights reserved.info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltextErectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Texthttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdfErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdfapplication/pdf279205https://repositorio.udes.edu.co/bitstreams/7cf70863-3f52-4a94-a1f3-445f29a5f6f7/download68d151b14479f430e7af476f1081f029MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/79a016d4-2af4-49f8-9061-b2984dd75356/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdf.txtErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/283db921-8590-4525-af6c-21251832c979/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdf.jpgErectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdf.jpgGenerated Thumbnailimage/jpeg7558https://repositorio.udes.edu.co/bitstreams/c94069b0-7a29-4f6f-8f72-7f157d9bc885/downloadbda582e577ed99e2df04b2fed3182157MD54001/6141oai:repositorio.udes.edu.co:001/61412023-10-09 18:23:23.6https://creativecommons.org/licenses/by-nc/4.0/© 2021 The Authors, Elsevier Ltd. All rights reserved.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=

Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial

Publicaciones similares